|
29.11.2021 |
EN |
Official Journal of the European Union |
C 481/24 |
Judgment of the General Court of 6 October 2021 — Dermavita Company v EUIPO — Allergan Holdings France (JUVEDERM)
(Case T-372/20) (1)
(EU trade mark - Revocation proceedings - EU word mark JUVEDERM - Genuine use of the mark - Use in connection with the goods in respect of which the mark is registered - Use with the consent of the proprietor - Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))
(2021/C 481/33)
Language of the case: English
Parties
Applicant: Dermavita Company S.a.r.l. (Beirut, Lebanon) (represented by: D. Todorov, lawyer)
Defendant: European Union Intellectual Property Office (represented by: K. Zajfert, J. Crespo Carrillo and V.J. Ruzek, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Allergan Holdings France SAS (Courbevoie, France) (represented by: J. Day, Solicitor, and T. de Haan, lawyer)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 14 April 2020 (Case R 877/2019-4), relating to revocation proceedings between Dermavita Company and Allergan Holdings France.
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Dermavita Company S.a.r.l. to pay the costs of the present proceedings. |